These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1826740)

  • 21. [New, in Austria registered specialty drugs. Zofran (Ondansetron, Glaxo)].
    Erben M
    Wien Klin Wochenschr; 1991; 103(19):594-601. PubMed ID: 1836917
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of ondansetron in paediatric patients: a review of three studies.
    Stevens RF
    Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
    J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Curative effect of ondansetron on chemically-induced vomiting. Initial results].
    Marty M; Le Bonniec M
    Presse Med; 1991 Jul 6-13; 20(26):1233. PubMed ID: 1831900
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
    Einhorn LH; Nagy C; Werner K; Finn AL
    J Clin Oncol; 1990 Apr; 8(4):731-5. PubMed ID: 2138214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ondansetron to prevent vomiting after cancer chemotherapy.
    Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serotonin as mediator in vomiting reflex: effect of a serotonin3 receptor antagonist in chemotherapy-induced vomiting].
    Layer P
    Z Gastroenterol; 1991 May; 29(5):265-6. PubMed ID: 1835227
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
    Marschner N
    Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction: the clinical challenge.
    Schmoll HJ
    Eur J Cancer; 1991; 27 Suppl 1():S1-2. PubMed ID: 1831627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
    Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
    Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
    Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
    Italian Group For Antiemetic Research
    J Clin Oncol; 2004 Feb; 22(4):725-9. PubMed ID: 14966097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
    Vrabel M
    Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
    Hainsworth JD
    Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
    Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
    N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.